Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

(2014) Conrad Eng et al.   LANCET

Treatment Pattern of Type 2 Diabetes Differs in Two German Regions and with Patients' Socioeconomic Position

(2014) Teresa Tamayo et al.   PLoS One

Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK

(2013) G. C. Hall et al.   DIABETIC MEDICINE

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study

(2012) Stephan Matthaei et al.   Diabetes Therapy

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability

(2011) A. J. Garber   DIABETES CARE

Patient Factors Associated with Glucagonlike Peptide 1 Receptor Agonist use with and without Insulin

(2011) Irl Hirsch et al.   Endocrine Practice

Validity and representativeness of the “Disease Analyzer” patient database for use in pharmaco-epidemiological and pharmacoeconomic studies

(2011) H. Becher et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine

(2009) Rosalind Fabunmi et al.   CURRENT MEDICAL RESEARCH AND OPINION